Repros’ New IND for the Investigation of Androxal® in the Treatment - PR Inside
The FDA noted no clinical hold issues but added that it may have some comments on the specifics of the Phase II design. Doses to be tested in the For more information, please visit the Company's website at www.reprosrx.com : .